Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease

TLDR

Alzheimer’s disease is a progressive neurodegenerative disorder marked by memory decline, neuronal loss, and amyloid plaques, yet in the Tg2576 mouse model age‑related memory impairment occurs without neuronal loss or Aβ accumulation. The study aims to test whether BAM‑10 neutralizes soluble Aβ assemblies to restore memory in Tg2576 mice. The authors hypothesize that BAM‑10 neutralizes small, soluble Aβ assemblies that disrupt cognition in Tg2576 mice. BAM‑10 administration fully reverses memory loss in Tg2576 mice without reducing Aβ levels, abolishing the inverse correlation between brain Aβ and memory and showing that much of the memory deficit is reversible.

Abstract

Alzheimer9s disease (AD) is a neurodegenerative condition, believed to be irreversible, characterized by inexorable deterioration of memory and intellect, with neuronal loss accompanying amyloid plaques and neurofibrillary tangles. In an amyloid precursor protein transgenic mouse model, Tg2576, little or no neuronal loss accompanies age-related memory impairment or the accumulation of Aβ, a 40–42 aa polypeptide found in plaques. Recently, we have shown inverse correlations between brain Aβ and memory in Tg2576 mice stratified by age (Westerman et al., 2002). Broadening the age range examined obscured this relationship, leading us to propose that small, soluble assemblies of Aβ disrupt cognitive function in these mice. Here we show that memory loss can be fully reversed in Tg2576 mice using intraperitoneally administered BAM-10, a monoclonal antibody recognizing the N terminus of Aβ. The beneficial effect of BAM-10 was not associated with a significant Aβ reduction, but instead eliminated the inverse relationship between brain Aβ and memory. We postulate that BAM-10 acts by neutralizing Aβ assemblies in the brain that impair cognitive function. Our results indicate that a substantial portion of memory loss in Tg2576 mice is not permanent. If these Aβ assemblies contribute significantly to memory loss in AD, then successfully targeting them might improve memory in some AD patients.